Rituximab in Combination with CHOP, an Effective and Well-tolerated Salvage Regimen for Diffuse Large B-Cell Lymphoma

作     者：Yong Guan Zhenxia Lu Butong Sun Lintao Bi Pengyu Zhang 

作者机构：Department of Hematology and Oncology China-Japan Union Hospital Changchun 130033 China. Department of Hematology and Oncology China-Japan Union Hospital Changchun 130033 China Clinical Laboratory rianjin Medical University Cancer Institute ＆ Hospital Tianjin 300060 China. 

出 版 物：《Chinese Journal of Clinical Oncology》 (中国肿瘤临床（英文版）)

年 卷 期：2007年第4卷第4期

页      面：264-267页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：large cell lymphoma diffuse rituximab CHOP regimen. 

摘      要：OBJECTIVE To evaluate the clinical effect of the R-CHOP regimen (rituximab in combination with cyclophosphamide, epirubicin, vincristine and prednisone) in treating refractory or relapsed diffuse large B-cell lymphoma (DLBCL), as a salvage therapy for DLBCL. METHODS Eighteen patients with refractory or relapsed DLBCL who were treated with the R-CHOP regimen from 2001 to 2006 in hospitals in Jilin Province were analyzed retrospectively. The response rate, change of serum lactate dehydrogenase (LDH), time to progression (TTP) and toxicity were observed. RESULTS The R-CHOP regimen can achieve a higher response rate, decrease serum LDH to a larger extent and obtain longer TTP than a con- ventional secondary regimen. The main adverse effects were similar to con- ventional chemotherapy. CONCLUSION The R-CHOP regimen is one of the most effective sec- ondary therapies for DLBCL.